Alpha Cognition (NASDAQ:ACOG – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.
ACOG has been the subject of a number of other reports. HC Wainwright raised their price objective on Alpha Cognition from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Raymond James Financial set a $21.00 target price on Alpha Cognition and gave the company an “outperform” rating in a report on Thursday. B. Riley Financial assumed coverage on Alpha Cognition in a report on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Craig Hallum reissued a “buy” rating and set a $17.00 target price on shares of Alpha Cognition in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating. According to MarketBeat, Alpha Cognition currently has an average rating of “Buy” and a consensus price target of $18.20.
Check Out Our Latest Research Report on Alpha Cognition
Alpha Cognition Price Performance
NASDAQ ACOG opened at $8.30 on Friday. The company has a market capitalization of $180.77 million, a price-to-earnings ratio of -6.06 and a beta of 2.32. Alpha Cognition has a twelve month low of $4.50 and a twelve month high of $10.14. The stock has a fifty day simple moving average of $8.74 and a 200 day simple moving average of $7.28.
Alpha Cognition (NASDAQ:ACOG – Get Free Report) last announced its earnings results on Wednesday, November 11th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Alpha Cognition had a negative return on equity of 52.80% and a negative net margin of 147.26%. The company had revenue of $7.78 million for the quarter, compared to analyst estimates of $7.04 million. Research analysts expect that Alpha Cognition will post -1.27 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Robert Wills purchased 10,000 shares of the business’s stock in a transaction on Friday, August 21st. The shares were acquired at an average price of $9.62 per share, with a total value of $96,200.00. Following the completion of the transaction, the director owned 32,241 shares of the company’s stock, valued at $310,158.42. The trade was a 44.96% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.60% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in ACOG. Pekin Hardy Strauss Inc. bought a new stake in shares of Alpha Cognition during the 3rd quarter valued at about $210,000. Marshall Wace LLP acquired a new stake in Alpha Cognition during the third quarter worth approximately $449,000. ACT Capital Partners L.P. bought a new stake in Alpha Cognition in the third quarter worth approximately $464,000. Aristides Capital LLC increased its holdings in Alpha Cognition by 1.4% in the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock worth $1,200,000 after purchasing an additional 3,052 shares in the last quarter. Finally, AWM Investment Company Inc. bought a new stake in Alpha Cognition in the second quarter worth approximately $12,073,000.
Alpha Cognition Company Profile
Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.
See Also
- Five stocks we like better than Alpha Cognition
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
